There were 1,823 press releases posted in the last 24 hours and 393,408 in the last 365 days.

Cancer Drugs Market Size Worth Around US$ 272 Billion by 2030

According to Precedence Research, the global cancer drugs market size is expected to be worth around US$ 272 billion by 2030 from at US$ 136.2 billion in 2020, growing at a CAGR of 7.2% from 2021 to 2030.

Ottawa, Dec. 17, 2021 (GLOBE NEWSWIRE) -- The global cancer drugs market growth driven by the rising prevalence of various types of cancer such as lungs cancer, colorectal cancer, bowel cancer, breast cancer, and various other types of cancer. The International Agency for Research on Cancer, in its report GLOBOCAN, has published that around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe, in 2020. The lungs cancer was the most prominent cancer followed by the breast cancer.

Get the Report Sample Copy for more understanding@

Moreover, the increasing awareness regarding the availability of various new therapies to treat cancer is fueling the demand for the cancer drugs among the global cancer patients. Furthermore, the rising investments by the biopharmaceutical companies in the development of new cancer drugs and diagnostic devices are fostering the growth of the cancer drugs market. Moreover, the rising adoption of the health insurance and favorable reimbursement policies is encouraging the patients to adopt the latest therapies to treat cancer by providing them with financial support. This is further boosting the growth of the cancer drugs market across the globe.

Scope of the Cancer Drugs Market

Report Coverage Details
Market Size in 2030 USD 272 Billion
Growth Rate CAGR of 7.2% from 2021 to 2030
Largest Market North America
Base Year 2021
Forecast Period 2021 to 2030
Companies Mentioned Amgen, Bayer Healthcare AG, CELGENE CORPORATION, GlaxoSmithKline, ARIAD Pharmaceuticals, Inc., Eli Lilly and Company, Novartis, Hoffmann-La Roche Ltd., AstraZeneca, BoehringerIngelheim GmbH, Pfizer, Teva Pharmaceuticals Industries

Regional Snapshot

North America dominated the global cancer drugs market in 2020. The increased prevalence of the cancer, higher healthcare expenditure, increasing awareness regarding the new biopharmaceutical drugs, presence of the world’s top drug manufacturers, and the presence of sophisticated and developed healthcare infrastructure in the region are the major drivers of the cancer drugs market in North America. According to the American Cancer Society, over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020.

View Full Report Information@

Europe is estimated to be the fastest-growing market in 2020. The Europe is characterized by the rapidly growing incidences of cancer, increased disposable income, growing health awareness, and rising demand for the advanced therapies.

Market Dynamics


Rising prevalence of the cancer among the population

The most important and the most prominent driver of the cancer drugs is the growing prevalence of the cancer among the global population. The rapid developments in the field of biopharmaceuticals and the favorable reimbursement policies are significantly driving the demand for the cancer drugs among the population.


High cost of the cancer drugs

The high cost associated with the cancer drugs is a major factor that may restrict the middle and low income people to adopt the expensive cancer therapies, especially in the underdeveloped and developing economies. Furthermore, the lack of awareness among the people is another factor that may hamper the market growth during the forecast period.


The increasing adoption of healthcare insurance

The high costs related to the healthcare and rising burden of diseases and infections across the globe is encouraging the population to opt for a healthcare insurance. The various medical and financial support in the form of reimbursements and medical claims provided by the healthcare insurances is expected to drive the adoption of the cancer immunotherapy among the cancer patients across the globe.


Lack of access to healthcare facilities

The low and inadequate healthcare infrastructure in the developing and the underdeveloped economies results in the low access to the healthcare facilities. In most of the cases, the people suffering from cancer remain undiagnosed and untreated. This is a major challenge to the market players that may restrict them to grow further.

Get Customization Study, Ask here@

Report Highlights

  • Based on the drug class, the targeted therapy dominated the market in 2020. The increased awareness regarding the benefits of the targeted therapy over the traditional chemotherapy has significantly boosted the adoption of the targeted therapy among the patients. Moreover, the targeted therapy only targets the cancer cells and avoids the normal cells, which results in low side-effects. The efficiency of the targeted therapy in the treatment of the cancer cells has fostered the growth of this segment especially in the developed markets like North America and Europe.

  • Based on the indication, the breast cancer is estimated to be the most opportunistic segment during the forecast period. The breast cancer has become the most diagnosed cancer by surpassing the lungs cancer in 2020. According to the International Agency for Research on Cancer, the breast cancer accounted for over 10% of the global cancer cases in 2020. Hence, the rising prevalence of the breast cancer among the global female population is expected to drive the market growth in the foreseeable future.

Segments Covered in the Report

By Drug Class

  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy

By Indication

  • Lungs Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Liver Cancer
  • Bladder Cancer
  • Head & Neck Cancer
  • Prostate Cancer
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Click Here to View Full Report Table of Contents

Buy this Premium Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

Primary Logo